Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH
A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 150 participants.
Also called NCT07102511
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 150 participants
- Registry
-
NCT07102511 -
2025-524214-28-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Israel, New Zealand, Norway, South Africa, Türkiye
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT07102511. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-20 (actual); primary completion 2028-07-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH
- Acronym
- LIBerateKids
- Condition
- Familial Hypercholesterolemia - Heterozygous
- Intervention (Biological)
- lerodalcibep 300 mg Monthly SC
- Lead sponsor
- LIB Therapeutics LLC
- Collaborator
- Medpace, Inc.
Record details
- Record id
cardio:ct-nct07102511- Content hash
f9a060fe26ed44b7aaa1b36084481fd6802f2b9f13ce2329a5f0c061896389f6